Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Cash & Equivalents (2016 - 2026)

Tenax Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $1.6 million for Q4 2017.

  • On a quarterly basis, Cash & Equivalents fell 83.95% to $1.6 million in Q4 2017 year-over-year; TTM through Dec 2017 was $1.6 million, a 83.95% decrease, with the full-year FY2017 number at $1.6 million, down 83.95% from a year prior.
  • Cash & Equivalents hit $1.6 million in Q4 2017 for Tenax Therapeutics, down from $1.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TENX hit a ceiling of $58.3 million in Q2 2014 and a floor of $722152.0 in Q3 2016.
  • Historically, Cash & Equivalents has averaged $7.3 million across 5 years, with a median of $3.1 million in 2015.
  • Biggest five-year swings in Cash & Equivalents: surged 7343.33% in 2014 and later plummeted 86.41% in 2015.
  • Tracing TENX's Cash & Equivalents over 5 years: stood at $783528.0 in 2013, then surged by 7343.33% to $58.3 million in 2014, then plummeted by 93.72% to $3.7 million in 2015, then skyrocketed by 173.08% to $10.0 million in 2016, then plummeted by 83.95% to $1.6 million in 2017.
  • Business Quant data shows Cash & Equivalents for TENX at $1.6 million in Q4 2017, $1.8 million in Q3 2017, and $2.2 million in Q2 2017.